Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

The forward-looking statements made in this announcement relate only to the events or information as of the date on which the statements are made in this announcement. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this announcement completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this announcement, statements of, or references to, our intentions or those of any of our directors and/or our Company are made as of the date of this announcement. Any of these intentions may alter in light of future development.

CStone Pharmaceuticals

基石藥業

(Incorporated in the Cayman Islands with limited liability)

(**Stock Code: 2616**)

VOLUNTARY ANNOUNCEMENT

CSTONE'S PARTNER BLUEPRINT MEDICINES ANNOUNCED AYVAKIT™ (AVAPRITINIB) APPROVED BY THE US FDA FOR THE TREATMENT OF ADULTS WITH UNRESECTABLE OR METASTATIC PDGFRA EXON 18 MUTANT GASTROINTESTINAL STROMAL TUMOR

Blueprint Medicines Corporation (NASDAQ: BPMC) ("**Blueprint Medicines**"), a partner of CStone Pharmaceuticals (the "**Company**" or "**CStone**"), is a precision therapy company focused on genomically-defined cancers, rare diseases and cancer immunotherapy. On January 9, 2020, Blueprint Medicines announced that the Food and Drug Administration of the United States ("**US FDA**") approved AYVAKIT™ (avapritinib) for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor ("**GIST**") harboring a platelet-derived growth factor receptor alpha ("**PDGFRA**") exon 18 mutation, including PDGFRA D842V mutations. Avapritinib was discovered by Blueprint Medicines.

Dr. Frank Ningjun Jiang, chairman, executive director and chief executive officer of CStone, commented: "I am very pleased that avapritinib, which we are developing in China through our partnership with Blueprint Medicines, has been approved in the U.S., making it the second drug candidate in CStone's pipeline that has received a US FDA approval. In 2020, CStone plans to submit a new drug application ("**NDA**") for the same indication to the Chinese National Medical Products Administration ("**NMPA**") to help address the unmet clinical needs of a genomically defined population of GIST patients in China."

Blueprint Medicines and CStone have entered into an exclusive collaboration and license agreement for the development and commercialization of three drug candidates, including avapritinib, in Mainland China,

Hong Kong, Macau and Taiwan. Blueprint Medicines retains the rights to develop and commercialize these three drug candidates in the rest of the world.

At present, two registrational trials of avapritinib for the treatment of GIST are being conducted in China. Among these trials, the Phase III VOYAGER trial of avapritinib in third-line therapy for GIST has completed its target enrollment of Chinese patients in less than four months. CStone plans to submit a NDA to the Chinese NMPA for avapritinib for the treatment of third-line therapy for GIST in the second half of 2020.

For more information about the US FDA approval for avapritinib, please visit: http://ir.blueprintmedicines.com/news-releases/news-release-details/blueprint-medicines-announces-fda-approval-ayvakittm-avapritinib.

About CStone

CStone is a biopharmaceutical company focused on developing and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide. Established in 2015, CStone has assembled a world-class management team with extensive experience in innovative drug development, clinical research, and commercialization. The company has built an oncology-focused pipeline of 15 drug candidates with a strategic emphasis on immuno-oncology combination therapies. Currently, five late-stage candidates are at pivotal trials. With an experienced team, a rich pipeline, a robust clinical development-driven business model and substantial funding, CStone's vision is to become globally recognized as a leading Chinese biopharmaceutical company by bringing innovative oncology therapies to cancer patients worldwide.

For more information about CStone, please visit: www.cstonepharma.com.

By order of the Board
CStone Pharmaceuticals
Dr. Frank Ningjun Jiang
Chairman

Suzhou, People's Republic of China, January 15, 2020

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Frank Ningjun Jiang as Chairman and Executive Director, Dr. Wei Li, Mr. Qun Zhao, Mr. Yanling Cao, Mr. Guobin Zhang and Dr. Lian Yong Chen as non-executive Directors, and Dr. Paul Herbert Chew, Mr. Ting Yuk Anthony Wu and Mr. Hongbin Sun as independent non-executive Directors.